In a similar manner, McDermott et al. reported that MET-dependent NSCLC cells activate EGFR as a mechanism of resistance to PF2341066 (an irreversible MET kinase inhibitor) using an increasing dose resistant cellular model [111]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.